Cargando…
Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds
Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044154/ https://www.ncbi.nlm.nih.gov/pubmed/21373641 http://dx.doi.org/10.1371/journal.pone.0017132 |
_version_ | 1782198691669475328 |
---|---|
author | Cinti, Caterina Taranta, Monia Naldi, Ilaria Grimaldi, Settimio |
author_facet | Cinti, Caterina Taranta, Monia Naldi, Ilaria Grimaldi, Settimio |
author_sort | Cinti, Caterina |
collection | PubMed |
description | Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy. |
format | Text |
id | pubmed-3044154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30441542011-03-03 Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds Cinti, Caterina Taranta, Monia Naldi, Ilaria Grimaldi, Settimio PLoS One Research Article Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy. Public Library of Science 2011-02-23 /pmc/articles/PMC3044154/ /pubmed/21373641 http://dx.doi.org/10.1371/journal.pone.0017132 Text en Cinti et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Cinti, Caterina Taranta, Monia Naldi, Ilaria Grimaldi, Settimio Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds |
title | Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds |
title_full | Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds |
title_fullStr | Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds |
title_full_unstemmed | Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds |
title_short | Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds |
title_sort | newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044154/ https://www.ncbi.nlm.nih.gov/pubmed/21373641 http://dx.doi.org/10.1371/journal.pone.0017132 |
work_keys_str_mv | AT cinticaterina newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds AT tarantamonia newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds AT naldiilaria newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds AT grimaldisettimio newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds |